US › Healthcare

Insight Molecular Diagnostics Inc. (IMDX)

US · Healthcare · Diagnostics & Research

$5.12+1.79%
Last close · 2026-08-04

Latest quarter · ended 2026-03-31

Revenue
$32,000
Revenue YoY
-98.5%
Net profit
$-4.3M
Profit YoY
+35.7%
EPS
$-0.12
EPS estimate
$-0.26
Net margin
-13,406.2%

EPS came in at -0.12 against a street estimate of -0.26 — a beat of 53.8%.

Key statistics

Market cap
$162.4M
Forward P/E
0.0
P/B
87.06
Book value
$-0.33
EPS (TTM)
$-1.51
52-week high
$8.51
52-week low
$2.33
50-day MA
$5.40
200-day MA
$5.48
Beta
1.82

Analyst view

with an average price target of $8.33.

Shareholding

Insiders
21.28%
Institutions
61.53%

Largest institutional holders

FundStake
BROADWOOD CAPITAL Inc36.95%
Awm Investment Company Inc8.69%
PURA VIDA INVESTMENTS, LLC2.93%
Alyeska Investment Group, L.P.2.60%
Vanguard Capital Management, LLC1.66%
Heights Capital Management Inc1.22%
Geode Capital Management, LLC0.81%
FNY Investment Advisers, LLC0.77%

See the full picture

Technicals, trade setups with a published hit rate, $AI analysis and earnings-call summaries for Insight Molecular Diagnostics Inc. — free to start.

Google PlayApp Store

Other Healthcare companies

Eli Lilly and CompanyJohnson & JohnsonAbbVie IncUnitedHealth Group IncorporatedMerck & Company IncNovartis AG ADRAstraZeneca PLCThermo Fisher Scientific IncNovo Nordisk A/SAmgen IncAbbott LaboratoriesGilead Sciences Inc

Data updated 2026-08-05.